At a glance
- Originator GlaxoSmithKline
- Class Antiarrhythmics
- Mechanism of Action Serotonin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atrial fibrillation; CNS disorders; Irritable bowel syndrome; Stroke
Most Recent Events
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 16 Nov 1999 Profile reviewed but no significant changes made
- 06 Sep 1996 Preclinical development for CNS disorders in United Kingdom (Unknown route)